Alimera Sciences shares are trading higher after Alliance Global Partners upgraded the stock from Neutral to Buy and raised its price target from $4.5 to $8.
Portfolio Pulse from Benzinga Newsdesk
Alimera Sciences' stock has been upgraded from Neutral to Buy by Alliance Global Partners, with the price target raised from $4.5 to $8.

June 12, 2023 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alimera Sciences' stock upgraded to Buy by Alliance Global Partners, with an increased price target of $8.
The upgrade from Neutral to Buy by Alliance Global Partners, along with the increased price target from $4.5 to $8, indicates a positive outlook for Alimera Sciences' stock. This is likely to result in a short-term increase in the stock price, as investors may perceive the stock as more attractive due to the upgrade and higher price target.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100